Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

Nokia Layoffs 2023: What to Know About the Latest NOK Job Cuts

By Larry Ramer, InvestorPlace Contributor

Nokia (NOK) stock is retreating after the telecom-equipment company reported that it would lay off up to 16% of its employees.  

7 Stocks That Are Heading for a Train Wreck

By Larry Ramer, InvestorPlace Contributor

There's always a bear market somewhere. Here are seven stocks to sell that investors should definitely unload now.

Why PayPal Stock Is a Bargain After Its Sharp Pullback

By Larry Ramer, InvestorPlace Contributor

PayPal continues to be the leading fintech player in  the U.S., while the valuation of PYPL stock is extraordinarily low. 

Looking for a Strong EV Stock Bet? 4 Reasons NOT to Pick NIO.

By Larry Ramer, InvestorPlace Contributor

Nio's deliveries are trending downwards, and it lacks major competitive advantages. As a result, I believe that NIO stock can sink further. 

Tesla Stock Outlook: Is the Musk Bubble Finally Bursting?

By Larry Ramer, InvestorPlace Contributor

Tesla currently has multiple negative catalysts that could cause TSLA stock to meaningfully fall in the medium term. 

FDA Sends ARDX Stock Soaring After Approving Ardelyx’s Kidney Disease Drug

By Larry Ramer, InvestorPlace Contributor

ARDX stock is rallying after the U.S. Food and Drug Administration (FDA) approved Ardelyx's kidney disease treatment.

Instacart Outlook: Is CART Stock a Buy, Sell or Hold Post-IPO?

By Larry Ramer, InvestorPlace Contributor

Tough competition, limited appeal, and high valuation are all signs that Instacart may not present fortunate results for growth investors.

Are Robinhood Insiders Giving Up on HOOD Stock?

By Larry Ramer, InvestorPlace Contributor

The co-founder and Chief Creative Officer of Robinhood unloaded over 90,000 shares of HOOD stock recently. 

ChargePoint Forecast: What Will CHPT Stock Be Worth in 5 Years?

By Larry Ramer, InvestorPlace Contributor

With ChargePoint growing rapidly and likely to become profitable by 2028, I expect the price of CHPT stock to more than quadruple by then.

3 Stocks You Need to Own Before the Next Wave of Innovation Hits

By Larry Ramer, InvestorPlace Contributor

Successful innovations often spur huge stock gains. These three stocks to buy can get big boosts from promising initiatives. 

Load More